TNF and short bowel syndrome: In a previous meta‐analysis, 58% of patients with CD who underwent EBD were surgery‐free for 33 months, which was the mean follow‐up period, and the immediate success rate of EBD was satisfactory in terms of avoiding urgent surgery.10 IMs and anti‐TNFα were established to treat intestinal strictures to avoid repeated surgical resection and the related risk of short bowel syndrome, and to reduce the economic burden on the patients and society.11, 12, 13 In particular, anti‐TNFα could dramatically change the treatment strategy for CD.